Avalo Therapeutics, Inc. Common Stock
Symbol: AVTX (NASDAQ)
13.16
▲ (3.54%) 0.450
Company Description:
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Key Stats
- Today's Open: $12.8
- Today's High: $14.14
- Today's Low: $12.395
- Today's Volume: 453.45K
- Yesterday Close: $12.71
- Yesterday High: $13.29
- Yesterday Low: $12.61
- Yesterday Volume: 496.34K
- Last Min Volume: 119
- Last Min High: $13.161
- Last Min Low: $13.16
- Last Min VWAP: $13.16042
Company Profile
- Name: Avalo Therapeutics, Inc. Common Stock
- Website: https://www.avalotx.com
- Listed Date: 2015-11-13
- Location: WAYNE, PA
- Market Status: Active
- CIK Number: 0001534120
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $167.17M
- Round Lot: 100
- Outstanding Shares: 13.15M
- Asset Type: CS
RECENT FILINGS FOR AVTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-01 | 8-K | View |
| 2025-09-22 | 8-K | View |
| 2025-08-27 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-05 | SCHEDULE 13G | View |
| 2025-06-20 | 8-K | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 3 | View |
| 2025-06-18 | 8-K | View |
| 2025-06-17 | 8-K | View |
| 2025-06-05 | 8-K | View |
Latest News on AVTX